Thus, therapeutic stimulation of Axl functions in RA DCs to rebalance the immune system could bring clinical improvement in RA, similar to CTLA‐4 therapy, albeit with careful cancer risk factor monitoring. The gene discussed is AXL; the disease is rheumatoid arthritis.